Amikacin
Amikacin is an intervention with 22 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.9%
8 of 9 finished
11.1%
1 ended early
6
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Clinical Trials (22)
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA)."
Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis
the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy
Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
Amikacin Pharmacokinetics to Optimize Dosing Recommendations in Neonates With Perinatal Asphyxia Treated With Hypothermia
Fixed-dose Amikacin for Elderly UTI
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria
DDI Study to Investigate Interaction Between Amikacin and POL7080
Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis
Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 22